Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights

Mar 18, 2019

Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

Mar 15, 2019

Fortress Biotech to Present at the 31st Annual ROTH Conference

Mar 14, 2019

Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101

Mar 13, 2019

Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

Mar 13, 2019

Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

Mar 12, 2019

Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme

Feb 20, 2019

Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation

Feb 12, 2019

Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

Feb 11, 2019

Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

Jan 31, 2019
RSS
  • Prev
    • 1...
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    • 59
    • ...72
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap